Evidence map›Paper›PMID 29091724›Full record

ArticlePloS one2017

Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains.

Ivette A Nuñez, Michael A Carlock, James D Allen, Simon O Owino, Krissy K Moehling, Patricia Nowalk, Michael Susick, Kensington Diagle, Kristen Sweeney, Sophia Mundle and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.

  1. [High-dose trivalent influenza vaccine: safety and immunogenicity].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2021
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Antiviral CD4Communications medicine · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Ivette A NuñezCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, United States of America.
Michael A CarlockCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, United States of America.
James D AllenCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, United States of America.
Simon O OwinoCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, United States of America.
Krissy K MoehlingDepartment of Family Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Patricia NowalkDepartment of Family Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Michael SusickDepartment of Family Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Kensington DiagleMartin Health System, Clinical Research Division, Stuart, Florida, United States of America.
Kristen SweeneyMartin Health System, Clinical Research Division, Stuart, Florida, United States of America.
Sophia MundleSanofi Pasteur, Inc., Research North America, Cambridge, Massachusetts, United States of America.
Thorsten U VogelSanofi Pasteur, Inc., Research North America, Cambridge, Massachusetts, United States of America.
Simon DelagraveSanofi Pasteur, Inc., Research North America, Cambridge, Massachusetts, United States of America.
Moti RamgopalMartin Health System, Clinical Research Division, Stuart, Florida, United States of America.
Richard K ZimmermanDepartment of Infectious Diseases, University of Georgia, Athens, Georgia, United States of America.
Harry KleanthousMartin Health System, Clinical Research Division, Stuart, Florida, United States of America.
Ted M RossCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, United States of America.ORCID http://orcid.org/0000-0003-1947-7469
University of Georgia · USMartin Health System · USSanofi (United States) · USUniversity of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most humans have pre-existing immunity to influenza viruses. In this study, volunteers (ages of 18-85 years) were vaccinated with split, inactivated Fluzone™ influenza vaccine in four consecutive influenza seasons from 2013 to 2016 seasons. The impact of repeated vaccination on breadth and durability of antibodies was assessed as a result of vaccine strain changes. Total IgG anti-hemagglutinin (HA) binding antibodies and hemagglutination-inhibition (HAI) activity increased in all age groups against both influenza A HA components in the vaccine post-vaccination (day 21). However, younger subjects maintained seroprotective titers to the vaccine strains, which resulted in higher seroconversion rates in the elderly, since the HAI titers in elderly subjects were more likely to decline prior to the next season. Young subjects had significant HAI activity against historical, as well as contemporary H1 and H3 vaccine strains from the mid-1980s to present. In contrast, elderly subjects had HAI activity to H1 strains from all years, but were more likely to have HAI activity to older strains from 1918-1950s. They also had a more restricted HAI profile against H3 viruses compared to young subjects recognizing H3N2 influenza viruses from the mid-2000s to present. Vaccine recipients were then categorized by whether subjects seroconverted from a seronegative or seropositive pre-vaccination state. Regardless of age, immunological recall or 'back-boosting' to antigenically related strains were associated with seroconversion to the vaccine strain. Overall, both younger and older people have the ability to mount a breadth of immune responses following influenza vaccination. This report describes how imprinting exposure differs across age groups, influences antibody cross-reactivity to past hemagglutinin antigenic variants, and shapes immune responses elicited by current split inactivated influenza vaccines. Understanding how current influenza vaccines are influenced by pre-existing immunity in people of different ages is critical for designing the next-generation of 'universal' or broadly-protective influenza vaccines.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, ViralEnzyme-Linked Immunosorbent AssayFemaleHumansInfluenza VaccinesMaleMiddle AgedYoung AdultAntibodies, ViralInfluenza Vaccines

Identifiers

PMID29091724
PMCPMC5665503
OpenAlexW2766363514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.